Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models


Disclosures: Institutional research funds from Menarini Ricerche S.p.A. (to F.B).


Alerto J. Arribas: travel grant from Astra Zeneca. HTG Luciano Cascione: travel grant from HTG. Afua Adjejwaa Mensah: travel grant from Helsinn. Davide Rossi: grant support from Gilead, AbbVie, Janssen; honoraria from Gilead, AbbVie Janssen, Roche; scientific advisory board fees from Gilead, AbbVie, Janssen, AstraZeneca, MSD. Georg Stussi: travel grants from Novartis, Celgene, Roche; consultancy fee from Novartis; scientific advisory board fees from Bayer, Celgene, Janssen, Novartis; speaker fees from Gilead. Anastasios Statthis: institutional research funds from: Bayer, ImmunoGen, Merck, Pfizer, Novartis, Roche; travel grant from AbbVie. Emanuele Zucca: institutional research funds from Celgene, Roche and Janssen; advisory board fees from Celgene, Roche, Mei Pharma, Astra Zeneca and Celltrion Healthcare; travel grants from Abbvie and Gilead; expert statements provided to Gilead, Bristol-Myers Squibb and MSD. Francesco Bertoni: institutional research funds from Acerta, ADC Therapeutics, Bayer AG, Cellestia, CTI Life Sciences, EMD Serono, Helsinn, ImmunoGen, Menarini Ricerche, NEOMED Therapeutics 1, Oncology Therapeutic Development, PIQUR Therapeutics AG; consultancy fee from Helsinn, Menarini; expert statements provided to HTG; travel grants from Amgen, Astra Zeneca, Janssen-Cilag AG, Jazz Pharmaceuticals, PIQUR Therapeutics AG. The other co-authors do not report any conflict of interest.

Contributions: MoB and FB provided conception and design; EG, CT, FS designed and performed experiments, analyzed results, and prepared figures; FG, GS, RPB, AJA, LC, MaB, GM, AF, AB, AAM, GG, EB: performed experiments; RL performed genotyping for cell identity; RSB, RLD, AB, NA, CR performed immunohistochemistry on clinical specimens; GS provided personnel, contributed to data interpretation and manuscript revision; AP, MoB provided reagents; DR, EZ, GS, AS, MoB and FB contributed to data interpretation; FB provided study supervision and wrote the manuscript; all authors read and edited the manuscript.